Novel allergen-independent immunotherapy: positive data from a phase Ila pilot study with CpG contained in virus-like particles

Схожие документы

• Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.
  по: Klimek, L, и др.
  Опубликовано: (2014)
• Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
  по: Senti, G, и др.
  Опубликовано: (2009)
• Allergen-specific immunotherapy: regulatory T cells or allergen-specific IgG?
  по: Kündig, T, и др.
  Опубликовано: (2010)
• CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance
  по: Guillem Montamat, и др.
  Опубликовано: (2021-02-01)
• A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel allergen-independent immunotherapy in patients suffering from grass pollen allergy
  по: Senti, G, и др.
  Опубликовано: (2007)